Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combos aim to boost survival in Hard-to-Treat cancers

NCT ID NCT03281369

Terminated Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the immunotherapy atezolizumab (Tecentriq) and other drugs. The goal was to see if these combinations were safe and worked better than standard treatment alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atezolizumab (Tecentriq) plus chemotherapy (5-FU, leucovorin, oxaliplatin) and other immunotherapy drugs
What this could lead to
If successful, this could point toward more effective treatment combinations for advanced gastric and esophageal cancers, potentially improving survival and response rates.
What could go wrong
This is an early-phase (1b/2) umbrella study with multiple arms, so results are preliminary. The combinations may not prove better than standard chemotherapy and could have added side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma of esophagus esophageal cancer Esophageal Neoplasms gastric adenocarcinoma gastroesophageal adenocarcinoma gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA OR ESOPHAGEAL CARCINOMA

Contacts and locations

Locations

  • Barts and The London School of Medicine and Dentistry - Barts Cancer Institute (BCI)-CECM

    London, 0, United Kingdom

  • Beatson West of Scotland Cancer Centre

    Glasgow, G12 0YN, United Kingdom

  • Blacktown Hospital

    Blacktown, New South Wales, 2148, Australia

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Hospital Universitari Vall dHebron

    Barcelona, 08035, Spain

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • Mayo Clinic Cancer Center

    Scottsdale, Arizona, 85259, United States

  • Monash Medical Centre-Moorabbin Campus

    Clayton, Victoria, 3168, Australia

  • National Cheng Kung University Hospital

    Tainan, 70457, Taiwan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Rambam Health Care Campus

    Haifa, 3109601, Israel

  • Samsung Medical Center

    Seoul, 135-710, South Korea

  • Seoul National University Bundang Hospital

    Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 110-744, South Korea

  • Sourasky Medical Centre

    Tel Aviv, 64239, Israel

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Tennessee Oncology - Nashville

    Nashville, Tennessee, 37203, United States

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, 442-723, South Korea

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX, United Kingdom

  • The Royal Marsden

    London, SW7 3RP, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton

    Sutton, SM2 5PT, United Kingdom

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030-4000, United States

  • UCLA Jonsson Comprehensive Cancer Center

    Santa Monica, California, 90404, United States

  • Uni of Southern California

    Los Angeles, California, 90033, United States

  • Universidad de Navarra - Clinica Universitaria de Navarra (CUN)

    Pamplona, Navarre, 31008, Spain

  • University of Ulsan College of Medicine - Asan Medical Center (AMC) - Asan Cancer Center (ACC)

    Songpa-gu, 05505, South Korea

  • Yonsei University College of Medicine (YUCM)-Yonsei Cancer Center

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.